| 24.16 0.48 (2.03%) | 11-06 09:47 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 29.73 | 1-year : | 34.72 |
| Resists | First : | 25.45 | Second : | 29.73 |
| Pivot price | 23.31 |
|||
| Supports | First : | 23.14 |
Second : | 21.71 |
| MAs | MA(5) : | 24.14 |
MA(20) : | 23.18 |
| MA(100) : | 23.84 |
MA(250) : | 23.54 |
|
| MACD | MACD : | 0.3 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 78.2 |
D(3) : | 83.4 |
| RSI | RSI(14): 53.2 |
|||
| 52-week | High : | 27.97 | Low : | 19.39 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ELAN ] has closed below upper band by 38.8%. Bollinger Bands are 26% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 25.25 - 25.38 | 25.38 - 25.48 |
| Low: | 23.14 - 23.27 | 23.27 - 23.37 |
| Close: | 23.47 - 23.68 | 23.68 - 23.85 |
Elanco Animal Health, a firm dedicated to animal well-being, creates, produces, and commercializes a diverse array of solutions for both companion animals and livestock. For household pets, the company provides preventative health solutions, including parasiticides and vaccinations, designed to guard against common ailments like worms, fleas, and ticks, with notable brands such as Seresto, Advantage, Advantix, and Advocate. Additionally, Elanco supplies therapeutic treatments for canine and feline conditions including pain, osteoarthritis, ear infections, cardiovascular issues, and dermatological problems, marketed under labels like Galliprant and Claro. Its portfolio for agricultural animals encompasses vaccines, antibiotics, parasiticides, and other essential products for poultry and aquaculture farming. This segment also features nutritional supplements such as enzymes, probiotics, and prebiotics to support animal health and growth. Furthermore, the company offers a comprehensive suite of products for ruminant and swine operations, comprising vaccines, antibiotics, implants, and parasiticides, often recognized by brands like Rumensin and Baytril. Elanco distributes its offerings through various channels, including independent distributors, veterinary clinics, and a broad spectrum of farm animal producers, from cattle and dairy farms to pig, poultry, and aquaculture enterprises. Established in 1954, Elanco Animal Health Incorporated maintains its corporate headquarters in Greenfield, Indiana.
Fri, 06 Nov 2026
ELAN: Revenue growth, margin expansion and a return to quarterly profit marked Q3 - TradingView
Fri, 06 Nov 2026
Elanco raises 2026 outlook as Q3 revenue grows 11% to $1.265 billion - grafa.com
Fri, 06 Nov 2026
Elanco Animal Health Shares Jump 7.6% as Q3 Earnings Beat Forecasts and Company Raises 2026 Outlook - Yahoo Finance
Fri, 06 Nov 2026
Elanco Animal Health (NYSE:ELAN) Jumps on Q3 Earnings Beat and Raised Outlook - ChartMill
Fri, 06 Nov 2026
Elanco Animal Health Reports Third Quarter 2026 Results - TradingView
Fri, 06 Nov 2026
Elanco Animal Health surges on Q3 beat and raised guidance - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 499 (M) |
| Shares Float | 495 (M) |
| Held by Insiders | 1.2 (%) |
| Held by Institutions | 115.5 (%) |
| Shares Short | 37,290 (K) |
| Shares Short P.Month | 30,920 (K) |
| EPS | -0.41 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 13.18 |
| Profit Margin | -4 % |
| Operating Margin | 8.6 % |
| Return on Assets (ttm) | 1.5 % |
| Return on Equity (ttm) | -3 % |
| Qtrly Rev. Growth | 10.1 % |
| Gross Profit (p.s.) | 5.56 |
| Sales Per Share | 10.05 |
| EBITDA (p.s.) | 2.02 |
| Qtrly Earnings Growth | 440.5 % |
| Operating Cash Flow | 617 (M) |
| Levered Free Cash Flow | 827 (M) |
| PE Ratio | -57.74 |
| PEG Ratio | 4 |
| Price to Book value | 1.79 |
| Price to Sales | 2.35 |
| Price to Cash Flow | 19.16 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|